The FDA launched the Commissioner's National Priority Voucher (CNPV) pilot program in June 2025 to expedite the approval of drugs and biologics related to national health priorities.[3][1] The program shortens the standard review time from 10-12 months to 1-2 months and includes increased communication and progressive review.[3][1][5] In October 2025, the FDA announced the first nine voucher recipients, including large firms such as Sanofi and Regeneron, as well as biotech companies such as Revolution Medicines.[3] Of these nine, five companies submitted applications, while four were proposed by FDA departments.[3] Applications are evaluated by a multidisciplinary committee led by FDA's Office of the Chief Medical and Scientific Officer based on consistency with priorities, preparedness, and impact on public health.[1][2] The vouchers are awarded in 2025, and after the pilot phase, the FDA can increase the number; they must expire within two years of issue.[2] However, the awarding process remains unclear, as many vouchers were awarded proactively without originally planned applications.[3]